Human polyomavirus 9 (HPyV9) is a non‑enveloped double‑stranded DNA virus belonging to the family Polyomaviridae. First identified in 2011 during polymerase chain reaction screening of tissues from immunocompromised individuals, HPyV9 is a component of the human skin flora.
Explanation
HPyV9 was originally detected in a kidney transplant recipient using a PCR assay targeting conserved polyomavirus sequences. Sequencing of the virus revealed a circular double‑stranded DNA genome of around 5 kilobases that encodes the canonical polyomavirus proteins: the small and large T antigens and the capsid proteins VP1, VP2 and VP3. Phylogenetically, HPyV9 is closely related to the African green monkey lymphotropic polyomavirus (LPV); the two viruses share roughly 75 % sequence identity. Cross‑reactivity studies show that antibodies against LPV can recognise HPyV9 and vice versa, explaining earlier reports of LPV seropositivity in humans. HPyV9 has been classified within the genus Alphapolyomavirus alongside murine polyomavirus. Serologic surveys indicate that HPyV9 exposure is less common than many other human polyomaviruses, with estimated seroprevalence ranging from about 30 % to 50 %. Detection of viral DNA in skin or bodily fluids is rare; studies report HPyV9 DNA in approximately 1 % of samples and no evidence of persistent shedding. Like other polyomaviruses, HPyV9 infection likely occurs in early life and remains latent in the host. Attempts to detect HPyV9 in tumour tissues have generally been negative or have yielded very low viral loads. The clinical significance of HPyV9 remains undefined. No clear disease association has been established, and the virus is not known to cause pathology even in immunocompromised individuals. Current evidence supports the view that HPyV9 is a benign member of the human virome.
Characteristics and Prevalence
HPyV9 stands out from other cutaneous polyomaviruses because of its close relation to the African green monkey lymphotropic polyomavirus. Serologic studies found that humans exposed to HPyV9 often generate antibodies that cross‑react with LPV antigens. Population surveys show HPyV9 seroprevalence between 30 % and 50 %, substantially lower than the 60–85 % seroprevalence observed for HPyV6 or HPyV7. Viral DNA has been detected in roughly 1 % of skin samples, and longitudinal studies have not observed persistent shedding. This combination of low DNA prevalence and moderate seropositivity suggests that HPyV9 infections are sporadic and well controlled by the immune system. The virus has not been reliably detected in tumour samples or linked to any specific disease, reinforcing its classification as a commensal virus. Human polyomavirus 9 is thus an infrequent but seemingly innocuous inhabitant of the human skin. Its discovery expanded the diversity of known polyomaviruses and underscored the potential for cross‑species viral lineages. At present, there is no evidence that HPyV9 causes disease in humans. Related Terms: Human Polyomavirus 6, Human Polyomavirus 7, MW Polyomavirus, STL Polyomavirus, New Jersey Polyomavirus